ImaginAb has collaborated with AstraZeneca, Pfizer and Takeda to develop technology to facilitate tumour imaging and monitoring inside the cells. ImaginAb is an emerging imaging company focused on immune-oncology. The technology also helps in targeting and visualizing CD8+ T cells, which are activated by the im...
Find MoreThe US FDA has approved Rybelsus (semaglutide) oral tablets to improve blood sugar in adult patients with Type II Diabetes. Rybelsus is an oral glucagon-like peptide (GLP-1) receptor protein treatment which has been approved after 15 years of the approval first GLP-1 agonist. GLP-1 is a hormone found in insuffi...
Find MoreAngioDynamics, an innovative medical devices provider, has signed an upfront USD 46 Million deal to acquire Eximo Medical. AngioDynamics is a leading player in manufacturing medical devices for vascular access, peripheral vascular disease, and oncology. The acquisition of Eximo Medical will increase the portfol...
Find MoreRoche’s Genentech has presented positive Phase III results from the IMvigor130 study aimed at studying Tecentriq (atezolizumab) tested in combination with platinum-based chemotherapy. The drug, Tecentriq, combined with Pt-based chemotherapy showed a noteworthy improvement in patients with untreated advanced bla...
Find MoreEuropean Commission Grants Orphan Drug Designation for Nirogacestat for the Treatment of Soft Tissue Sarcoma. Nirogacestat is a selective oral small molecule, gamma-secretase inhibitor under development by SpringWork Therapeutics. Currently, in Phase III development, the drug is investigated for the treatment o...
Find MoreFlagship Pioneering has launched Omega Therapeutics with an aim to take forward the genomic medicine. The launch of Omega therapeutics was planned to focus on epigenetic drugs to target diseases. Study of changes in gene expressions without any changes in the DNA sequence is known as Epigenetics. This oft...
Find MoreFUJIFILM Corporation has signed an exclusive licensing agreement with an Australian bio-venture Cynata Therapeutics Limited for CYP-001. Under the agreement, FUJIFILM will gain rights to develop, manufacture and market a drug for the treatment of graft-versus-host disease (GvHD). CYP-001 is a Cynata’s lead cand...
Find MoreAlivaMab Discovery Services (ADS) has announced an antibody discovery agreement against multiple targets with Janssen Research & Developments. AlivaMab, a pharmaceutical providing fully human therapeutic antibody discovery services, will render its therapeutic antibody candidates, its clinical expertise and...
Find MoreDaiichi Sankyo announced the submission of a New Drug Application (NDA) of DS-8201 to Japan's Ministry of Health, Labour and Welfare (MHLW). DS-8201 [fam-] trastuzumab deruxtecan), is an investigational antibody-drug conjugate (ADC) designed to deliver cytotoxic chemotherapy to cancer cells via a human epiderma...
Find MoreVertex Pharmaceuticals recently has announced the acquisition of Semma Therapeutics for USD 950 million in cash. Vertex Pharmaceuticals, aimed at creating therapies for life-threatening diseases, like cystic fibrosis, has signed a definitive agreement with Semma therapeutics, working to bring in the Healthcare ...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.